뒤로
Clarity Pharmaceuticals Ltd(CLRPF) 가격
CLRPF 주가 차트
CLRPF 재무
Clarity Pharmaceuticals Ltd
$2.3
2.22%
$0.04
종가: Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
수입
자산 및 부채 명세서
현금 흐름
연간
분기별
CLRPF 소득
미화 수백만 달러. 회계 연도는 2월부터 1월까지입니다.
Follow-Up Questions
Clarity Pharmaceuticals Ltd의 주요 재무제표는 무엇인가요?
CLRPF의 주요 재무 비율은 무엇인가요?
Clarity Pharmaceuticals Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Clarity Pharmaceuticals Ltd은 수익성이 있나요?
Clarity Pharmaceuticals Ltd에 부채가 있나요?
Clarity Pharmaceuticals Ltd의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$2.25
시가
$2.3
일일 범위
$2.3 - $2.3
52주 범위
$0.842 - $3.6
거래량
--
평균 거래량
3.1K
EPS(TTM)
-0.13
배당수익률
--
시가총액
$855.6M
CLRPF란 무엇인가요?
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing targeted copper theranostics based on its SAR Technology Platform. The company is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.